Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Calcitriol treatment is not effective in postmenopausal osteoporosis.

Ott SM, Chesnut CH 3rd.

Ann Intern Med. 1989 Feb 15;110(4):267-74.

PMID:
2913914
2.
3.

Calcitriol in the treatment of postmenopausal osteoporosis.

Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH.

Am J Med. 1988 Mar;84(3 Pt 1):401-8.

PMID:
3279769
4.

Low-dose calcitriol versus calcium in established postmenopausal osteoporosis.

Tilyard M.

Metabolism. 1990 Apr;39(4 Suppl 1):50-2.

PMID:
2325572
5.

Role of calcitriol in the treatment of postmenopausal osteoporosis.

Aloia JF.

Metabolism. 1990 Apr;39(4 Suppl 1):35-8.

PMID:
2182976
6.

Long-term treatment with calcitriol in postmenopausal osteoporosis.

Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G.

Metabolism. 1990 Apr;39(4 Suppl 1):43-9.

PMID:
2325571
7.

Treatment of postmenopausal osteoporosis with calcitriol or calcium.

Tilyard MW, Spears GF, Thomson J, Dovey S.

N Engl J Med. 1992 Feb 6;326(6):357-62.

8.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
9.
10.

Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol.

Falch JA, Odegaard OR, Finnanger AM, Matheson I.

Acta Med Scand. 1987;221(2):199-204.

PMID:
3035879
12.

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R.

Osteoporos Int. 2000;11(1):83-91.

PMID:
10663363
14.
15.

Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial.

LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE.

Ann Intern Med. 2000 Oct 3;133(7):516-26.

PMID:
11015164
16.

Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.

Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR.

Ann Intern Med. 1995 Sep 15;123(6):401-8.

PMID:
7639438
17.

Strontium ranelate in osteoporosis.

Reginster JY.

Curr Pharm Des. 2002;8(21):1907-16. Review.

PMID:
12171530
18.

Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.

Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD.

Am J Med. 2000 Oct 1;109(5):362-70.

PMID:
11020392
19.

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.

Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K; Probone Study Group.

Osteoporos Int. 2002 Dec;13(12):937-47.

PMID:
12459936
20.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193

Supplemental Content

Support Center